Sue Fletcher

Cited by

	All	Since 2020
Citations	13660	5748
h-index	61	36
i10-index	171	122

1400

700

350

1050

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202539 44 66 80 99 152 134 217 283 310 288 383 311 357 385 496 530 1024 500 730 1313 840 1116 1275 1234 1160 101

Public access

View all

73 articles

8 articles

available

not available

Based on funding mandates

Co-authors

Steve WiltonFoundation Chair in Molecular Therapies, Murdoch UniversityVerified email at ccg.murdoch.edu.au
Christopher J Mann, PhDMotivate Training LtdVerified email at motivate-training.com
Chalermchai MitrpantDepartment of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol UniversityVerified email at mahidol.edu
Ianthe PitoutMurdoch UniversityVerified email at ccg.murdoch.edu.au
Loren Flynn (Price)Perron Institute for Neurological and Translational Science and Murdoch UniversityVerified email at murdoch.edu.au
Francis MastagliaProfessor and Deputy Director, Institute for Immunology and Infectious Diseases, Murdoch University, Western AustraliaVerified email at iiid.murdoch.edu.au
Professor Matt BellgardPro Vice Chancellor, University of East LondonVerified email at uel.ac.uk
Nigel LAINGNeurogenetics, University of Western Australia, Harry Perkins Institute of Medical ResearchVerified email at uwa.edu.au
Craig S McIntoshCentre for Molecular Medicine and Innovative Therapeutics, Murdoch UniversityVerified email at murdoch.edu.au
Sudhir AgrawalARNAY SciencesVerified email at arnaysciences.com
jej raskoCentenary InstituteVerified email at cenint.org
Kay DaviesProfessor of Genetics University of OxfordVerified email at dpag.ox.ac.uk
Kay OhlendieckProfessor Biology, Maynooth UniversityVerified email at mu.ie
Arthur BurghesProfessor Molecular and Cellular BiochemistryVerified email at osu.edu
André SchultzRespiratory Physician, Perth Children's HospitalVerified email at health.wa.gov.au
Roberto BarreroQueensland University of TechnologyVerified email at qut.edu.au
Alan BittlesSchool of Medical and Health Sciences, Edith Cowan University and Centre for Comparative GenomicsVerified email at ecu.edu.au
Kathryn R NapierLead Data Scientist, COKI Project, Curtin Institute for Data ScienceVerified email at curtin.edu.au
Tarun WeeramanthriAdjunct Professor, School of Population Health, University of Western AustraliaVerified email at health.wa.gov.au
Haiyan ZhouUniversity College LondonVerified email at ucl.ac.uk

Sue Fletcher

Professor

Verified email at murdoch.edu.au

RNA therapeutics antisense technology neurodegenerative disease rare diseases


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
ALS genetics, mechanisms, and therapeutics: where are we now? R Mejzini, LL Flynn, IL Pitout, S Fletcher, SD Wilton, PA Akkari Frontiers in neuroscience 13, 1310, 2019	813	2019
Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements LW Barrett, S Fletcher, SD Wilton Cellular and molecular life sciences 69, 3613-3634, 2012	736	2012
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse QL Lu, CJ Mann, F Lou, G Bou-Gharios, GE Morris, S Xue, S Fletcher, ... Nature medicine 9 (8), 1009-1014, 2003	595	2003
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, HJC McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021	583	2021
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse CJ Mann, K Honeyman, AJ Cheng, T Ly, F Lloyd, S Fletcher, JE Morgan, ... Proceedings of the National Academy of Sciences 98 (1), 42-47, 2001	548	2001
Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript SD Wilton, AM Fall, PL Harding, G McClorey, C Coleman, S Fletcher Molecular Therapy 15 (7), 1288-1296, 2007	375	2007
Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD G McClorey, HM Moulton, PL Iversen, S Fletcher, SD Wilton Gene therapy 13 (19), 1373-1381, 2006	362	2006
Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides SD Wilton, F Lloyd, K Carville, S Fletcher, K Honeyman, S Agrawal, ... Neuromuscular disorders 9 (5), 330-338, 1999	358	1999
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022	356	2022
Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle BL Gebski, CJ Mann, S Fletcher, SD Wilton Human molecular genetics 12 (15), 1801-1811, 2003	286	2003
Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy CJ Mann, K Honeyman, G McClorey, S Fletcher, SD Wilton The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2002	280	2002
Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide S Fletcher, K Honeyman, AM Fall, PL Harding, RD Johnsen, SD Wilton The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2006	272	2006
Morpholino oligomer–mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse S Fletcher, K Honeyman, AM Fall, PL Harding, RD Johnsen, JP Steinhaus, ... Molecular Therapy 15 (9), 1587-1592, 2007	238	2007
Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping A Goyenvalle, A Babbs, D Powell, R Kole, S Fletcher, SD Wilton, ... Molecular Therapy 18 (1), 198-205, 2010	176	2010
The influence of antisense oligonucleotide length on dystrophin exon skipping PL Harding, AM Fall, K Honeyman, S Fletcher, SD Wilton Molecular Therapy 15 (1), 157-166, 2007	164	2007
Induced dystrophin exon skipping in human muscle explants G Mcclorey, AM Fall, HM Moulton, PL Iversen, JE Rasko, M Ryan, ... Neuromuscular Disorders 16 (9-10), 583-590, 2006	155	2006
Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene SJ Errington, CJ Mann, S Fletcher, SD Wilton The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2003	148	2003
Antisense oligonucleotides for inducing exon skipping and methods of use thereof SD Wilton, S Fletcher, G McClorey US Patent 7,807,816, 2010	138	2010
Antisense oligonucleotides for inducing exon skipping and methods of use thereof SD Wilton, S Fletcher, G McClorey US Patent 8,232,384, 2012	134	2012
Antisense oligonucleotides for inducing exon skipping and methods of use thereof SD Wilton, S Fletcher, G McClorey US Patent 7,960,541, 2011	129	2011

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors